Brief: Hookipa Announces First Person Dosed In Phase 1A/B Clinical Trial Of Hb-400, In Collaboration With Gilead, For Treatment Of Hepatitis B
09/05/2023 13:12
May 9 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* HOOKIPA ANNOUNCES FIRST PERSON DOSED IN PHASE 1A/B
CLINICAL
TRIAL OF HB-400, IN COLLABORATION WITH GILEAD, FOR TREATMENT OF
HEPATITIS B
Source text for Eikon: ID:nGNX85N5d4
Further company coverage: HOOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)